.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Johnson and Johnson
Cantor Fitzgerald
UBS
Farmers Insurance
Mallinckrodt
Novartis
Citi
Merck
Harvard Business School

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,754,065

« Back to Dashboard

Which drugs does patent 8,754,065 protect, and when does it expire?


Patent 8,754,065 protects DESCOVY, GENVOYA, ODEFSEY, and VEMLIDY, and is included in four NDAs.

This patent has forty-four patent family members in thirty-seven countries.

Summary for Patent: 8,754,065

Title:Tenofovir alafenamide hemifumarate
Abstract: A hemifumarate form of 9-[(R)-2-[[(S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino]phenoxyphosphinyl]- methoxy]propyl]adenine (tenofovir alafenamide), and antiviral therapy using tenofovir alafenamide hemifumarate (e.g., anti-HIV and anti-HBV therapies).
Inventor(s): Liu; Dazhan (Alberta, CA), Shi; Bing (Foster City, CA), Wang; Fang (Foster City, CA), Yu; Richard Hung Chiu (San Francisco, CA)
Assignee: Gilead Sciences, Inc. (CA)
Application Number:13/586,358
Patent Claim Types:
see list of patent claims
Compound; Composition; Use; Process; Formulation;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Gilead Sciences IncDESCOVYemtricitabine; tenofovir alafenamide fumarateTABLET;ORAL208215-001Apr 4, 2016RXYesYes► Subscribe► Subscribe► SubscribeYYTREATMENT OF HIV INFECTION
Gilead Sciences IncGENVOYAcobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarateTABLET;ORAL207561-001Nov 5, 2015RXYesYes► Subscribe► Subscribe► SubscribeYYTREATMENT OF HIV INFECTION
Gilead Sciences IncODEFSEYemtricitabine; rilpivirine hydrochloride; tenofovir alafenamide fumarateTABLET;ORAL208351-001Mar 1, 2016RXYesYes► Subscribe► Subscribe► SubscribeYYTREATMENT OF HIV INFECTION
Gilead Sciences IncVEMLIDYtenofovir alafenamide fumarateTABLET;ORAL208464-001Nov 10, 2016RXYesYes► Subscribe► Subscribe► SubscribeYYTREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,754,065

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,296,769Tenofovir alafenamide hemifumarate► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,754,065

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Mexico336627► Subscribe
Mexico2014001549► Subscribe
Moldova, Republic of4508► Subscribe
Moldova, Republic of20140011► Subscribe
Morocco35350► Subscribe
Lithuania2744810► Subscribe
South Korea101612642► Subscribe
South Korea20140054068► Subscribe
Japan2016169228► Subscribe
Japan5956537► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Fish and Richardson
Argus Health
Mallinckrodt
Daiichi Sankyo
Boehringer Ingelheim
McKinsey
UBS
McKesson
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot